Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.

@article{Tebas2008EnfuvirtideDN,
  title={Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.},
  author={Pablo Tebas and Nicholas C Bellos and Christopher Lucasti and Gary Richmond and Eliot W Godofsky and Indravadan V. Patel and Yu-Yuan Chiu and Claire Evans and Lucy Rowell and Miklos P Salgo},
  journal={Journal of acquired immune deficiency syndromes},
  year={2008},
  volume={47 3},
  pages={342-5}
}
OBJECTIVE The aim of this study was to examine the influence of kidney disease and hemodialysis on the pharmacokinetics ofenfuvirtide. DESIGN An open-label, multicenter, parallel group study of HIV-1-infected patients with varying degrees of kidney dysfunction. METHODS A 90-mg dose of enfuvirtide was administered by subcutaneous injection to 3 groups of patients: group A, patients with normal kidney function; group B, patients with chronic kidney disease; and group C, patients with end… CONTINUE READING